These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33883825)

  • 41. Elevation of Urinary Liver-Type Fatty Acid-Binding Protein Is a Harbinger of Poor Patient Prognosis after Allogeneic Stem Cell Transplantation.
    Shingai N; Ota A; Kato K; Kondo K; Sadaga Y; Kato C; Sakai S; Kambara Y; Nabe Y; Asano K; Teshima K; Kurihara K; Ouchi F; Fujiwara H; Shimabukuro M; Inai K; Jinguji A; Toya T; Shimizu H; Najima Y; Kobayashi T; Sugaya T; Ando M; Doki N
    Transplant Cell Ther; 2024 Jan; 30(1):121.e1-121.e8. PubMed ID: 37813188
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biomarkers in the assessment of acute and chronic kidney diseases in the dog and cat.
    Cobrin AR; Blois SL; Kruth SA; Abrams-Ogg AC; Dewey C
    J Small Anim Pract; 2013 Dec; 54(12):647-55. PubMed ID: 24152019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Worsening Renal Function in Patients With Acute Heart Failure.
    Okubo Y; Sairaku A; Morishima N; Ogi H; Matsumoto T; Kinoshita H; Kihara Y
    J Card Fail; 2018 Aug; 24(8):520-524. PubMed ID: 30026130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
    Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
    Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease].
    Kamijo A; Sugaya T; Hikawa A; Kimura K
    Rinsho Byori; 2003 Mar; 51(3):219-24. PubMed ID: 12707994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
    Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K
    Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease.
    Abe M; Maruyama N; Oikawa O; Maruyama T; Okada K; Soma M
    Scand J Clin Lab Invest; 2015 Sep; 75(5):421-7. PubMed ID: 26067610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes.
    von Eynatten M; Baumann M; Heemann U; Zdunek D; Hess G; Nawroth PP; Bierhaus A; Humpert PM
    Eur J Clin Invest; 2010 Feb; 40(2):95-102. PubMed ID: 19912308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Repeated measurements of renal function in evaluating its decline in cats.
    Finch NC; Syme HM; Elliott J
    J Feline Med Surg; 2018 Dec; 20(12):1144-1148. PubMed ID: 29451445
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The biomarker for CKD: urinary L-FABP - from molecular function to clinical significance].
    Okazaki M; Oikawa T; Sugaya T
    Nihon Yakurigaku Zasshi; 2015 Jul; 146(1):27-32. PubMed ID: 26165339
    [No Abstract]   [Full Text] [Related]  

  • 51. The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.
    Hikasa S; Yasuda M; Hideta K; Kawakami M; Higasa S; Sawada A; Tokugawa T; Kimura T
    Clin Exp Nephrol; 2017 Dec; 21(6):971-977. PubMed ID: 27761670
    [TBL] [Abstract][Full Text] [Related]  

  • 52. L-FABP and IL-6 as markers of chronic kidney damage in children after hemolytic uremic syndrome.
    Lipiec K; Adamczyk P; Świętochowska E; Ziora K; Szczepańska M
    Adv Clin Exp Med; 2018 Jul; 27(7):955-962. PubMed ID: 29905409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urinary fatty acid binding protein in renal disease.
    Kamijo-Ikemori A; Sugaya T; Kimura K
    Clin Chim Acta; 2006 Dec; 374(1-2):1-7. PubMed ID: 16860300
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of Proteinuria in Dogs and Cats with Chronic Kidney Disease.
    Vaden SL; Elliott J
    Vet Clin North Am Small Anim Pract; 2016 Nov; 46(6):1115-30. PubMed ID: 27485278
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Major Adverse Cardiovascular Events in Patients With Hypertension.
    Okubo Y; Nakano Y; Tokuyama T; Hironobe N; Okamura S; Ikeuchi Y; Miyauchi S; Kihara Y
    Am J Hypertens; 2020 Jul; 33(7):604-609. PubMed ID: 32155236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats.
    Tanabe J; Ogura Y; Nakabayashi M; Nagai Y; Watanabe S; Sugaya T; Ohata K; Ichikawa D; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Ono Y; Kamijo-Ikemori A
    Kidney Blood Press Res; 2019; 44(6):1476-1492. PubMed ID: 31734667
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urinary Liver Type Fatty Acid Binding Protein Is Negatively Associated With Estimated Glomerular Filtration Rate in Renal Transplant Recipients With Graft Loss.
    Huang YC; Chang YS; Chen CC; Tsai SF; Yu TM; Wu MJ; Chen CH
    Transplant Proc; 2018 May; 50(4):1083-1086. PubMed ID: 29731071
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
    Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Inoue T; Node K
    Am J Nephrol; 2006; 26(1):82-6. PubMed ID: 16534182
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intestinal fatty acid-binding protein levels in patients with chronic renal failure.
    Okada K; Sekino M; Funaoka H; Sato S; Ichinomiya T; Murata H; Maekawa T; Nishikido M; Eishi K; Hara T
    J Surg Res; 2018 Oct; 230():94-100. PubMed ID: 30100046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-FABP: A novel biomarker of kidney disease.
    Xu Y; Xie Y; Shao X; Ni Z; Mou S
    Clin Chim Acta; 2015 May; 445():85-90. PubMed ID: 25797895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.